

Serial No: 09/835,699

Case No: 19258CC

Page No: - 2 -

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-3. (Canceled)

Claim 4. (Previously presented) A plasmid expression vector which induces anti-HSV antibodies or protective immune responses upon introduction into vertebrate tissue, wherein said vector comprises at least one gene encoding a carboxy-terminal truncated gB protein comprising the amino terminal 707 amino acids of wild type gB, said gene or genes being operably linked to a transcription promoter.

Claim 5. (Previously presented) The plasmid expression vector of Claim 4 which is V1Jns:ΔgB.

Claim 6. (Previously presented) A plasmid expression vector which induces anti-HSV antibodies or protective immune responses upon introduction into vertebrate tissue, wherein said vector comprises at least one gene encoding the HSV protein, gD, said gene or genes being operably linked to a transcription promoter.

Claim 7. (Previously presented) The plasmid expression vector of Claim 6 which is V1Jns:gD.

Claim 8. (Previously presented) A vaccine for inducing an immune response against HSV which comprises a first plasmid expression vector which expresses the HSV protein gD and a second plasmid expression vector which expresses a carboxy-terminal truncated gB protein.

Claim 9. (Previously presented) A vaccine of claim 8 wherein said first plasmid expression vector is V1Jns:gD.

Claim 10. (Previously presented) A vaccine of claim 8 wherein said second plasmid expression vector is V1Jns:ΔgB.

Serial No: 09/835,699

Case No: 19258CC

Page No: - 3 -

Claim 11. (Previously presented) A vaccine of claim 10 wherein said first plasmid expression vector is V1Jns:gD.

Claim 12. (Previously presented) A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the vaccine according to Claim 11 into a tissue of a vertebrate.

Claim 13. (Previously presented) A vaccine of Claim 11 further comprising a pharmaceutically acceptable carrier.

Claim 14. (Previously presented) A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing a plasmid expression vector into a tissue of a vertebrate, wherein said vector comprises at least one gene encoding at least one HSV protein or truncated protein, said gene or genes being operably linked to a transcription promoter.

Claim 15. (Canceled)

Claim 16. (Previously presented) A method for inducing immune responses in a vertebrate against HSV epitopes according to Claim 14, wherein said vector comprises a gene which encodes an HSV protein selected from a group consisting of gB, gC, gD, gH, gL, ICP27, and truncated gB.

Claims 17-20. (Canceled)

Claim 21. (Currently amended) A vaccine for inducing an immune response against HSV which comprises a plasmid expression vector comprising a gene encoding a carboxy-terminal of claim 20, wherein said plasmid expression vector comprises a truncated gB protein deletion comprising the amino terminal 707 amino acids of wild type gB, said gene being operably linked to a transcription promoter, and a pharmaceutically acceptable carrier.

Claim 22. (Previously presented) A vaccine of Claim 21, wherein the plasmid expression vector is V1Jns:ΔgB.

Serial No: 09/835,699

Case No: 19258CC

Page No: - 4 -

Claim 23. (Currently amended) A vaccine for inducing an immune response against HSV which comprises a plasmid expression vector comprising of Claim 19, wherein said plasmid expression vector comprises a gene which encodes the HSV protein, gD, said gene being operably linked to a transcription promoter, and a pharmaceutically acceptable carrier.

Claim 24. (Previously presented) A vaccine of Claim 23, wherein the plasmid expression vector is V1Jns:gD.

Claims 25-30. (Canceled)